Qizhi Tang

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients
    Qizhi Tang
    Department of Surgery, University of California San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA
    Transpl Int 25:1257-67. 2012
  2. doi request reprint Regulatory T-cell therapy for transplantation: how many cells do we need?
    Qizhi Tang
    Department of Surgery, University of California, San Francisco, California 94143 0780, USA
    Curr Opin Organ Transplant 17:349-54. 2012
  3. pmc CD4(+)Foxp3(+) regulatory T cell therapy in transplantation
    Qizhi Tang
    Division of Transplantation, Department of Surgery, University of California San Francisco, San Francisco, CA 94143 0780, USA
    J Mol Cell Biol 4:11-21. 2012
  4. pmc Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, California, USA
    Nat Immunol 10:1185-92. 2009
  5. pmc Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice
    Craig Meagher
    Diabetes Center, University of California, San Francisco, CA 94143, USA
    J Immunol 180:7793-803. 2008
  6. pmc Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues
    Kristin Melli
    Department of Surgery, University of California, San Francisco, CA 94143, USA
    J Immunol 182:2590-600. 2009
  7. pmc Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice
    Amar Nijagal
    Eli and Edythe Broad Center of Regeneration Medicine and
    Blood 121:4595-602. 2013
  8. pmc Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction
    Qizhi Tang
    Department of Surgery, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143 0540, USA
    Immunity 28:687-97. 2008
  9. pmc Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs
    Cristina Penaranda
    Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    Diabetes 59:1461-8. 2010
  10. pmc Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts
    Todd V Brennan
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Surg Res 169:e69-75. 2011

Research Grants

Collaborators

Detail Information

Publications25

  1. doi request reprint Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients
    Qizhi Tang
    Department of Surgery, University of California San Francisco, 513 Parnassus Ave, San Francisco, CA 94143, USA
    Transpl Int 25:1257-67. 2012
    ....
  2. doi request reprint Regulatory T-cell therapy for transplantation: how many cells do we need?
    Qizhi Tang
    Department of Surgery, University of California, San Francisco, California 94143 0780, USA
    Curr Opin Organ Transplant 17:349-54. 2012
    ....
  3. pmc CD4(+)Foxp3(+) regulatory T cell therapy in transplantation
    Qizhi Tang
    Division of Transplantation, Department of Surgery, University of California San Francisco, San Francisco, CA 94143 0780, USA
    J Mol Cell Biol 4:11-21. 2012
    ....
  4. pmc Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, California, USA
    Nat Immunol 10:1185-92. 2009
    ..Blockade of the immunomodulatory receptor CTLA-4 did not alter T cell motility or abrogate tolerance. Thus, PD-1-PD-L1 interactions maintain peripheral tolerance by mechanisms fundamentally distinct from those of CTLA-4...
  5. pmc Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice
    Craig Meagher
    Diabetes Center, University of California, San Francisco, CA 94143, USA
    J Immunol 180:7793-803. 2008
    ..CD28KO mice provides an excellent model for the study of disease pathogenesis and development of new therapies for human autoimmune pancreatitis...
  6. pmc Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues
    Kristin Melli
    Department of Surgery, University of California, San Francisco, CA 94143, USA
    J Immunol 182:2590-600. 2009
    ..Therapeutic interventions that intercept this process may be effective at halting the progression of type 1 diabetes...
  7. pmc Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice
    Amar Nijagal
    Eli and Edythe Broad Center of Regeneration Medicine and
    Blood 121:4595-602. 2013
    ..Thus, tolerance induction after IUHCTx depends on both direct and indirect antigen presentation and is secondary to thymic deletion, without de novo Treg induction...
  8. pmc Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction
    Qizhi Tang
    Department of Surgery, University of California, San Francisco, 513 Parnassus Avenue, Box 0540, San Francisco, CA 94143 0540, USA
    Immunity 28:687-97. 2008
    ..Together, these results suggest intra-islet Treg cell dysfunction secondary to defective IL-2 production is a root cause of the progressive breakdown of self-tolerance and the development of diabetes in nonobese diabetic mice...
  9. pmc Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs
    Cristina Penaranda
    Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    Diabetes 59:1461-8. 2010
    ..In this study, we address the role of tertiary lymphoid organs (TLOs) that form in the pancreas of NOD mice during disease progression...
  10. pmc Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts
    Todd V Brennan
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Surg Res 169:e69-75. 2011
    ....
  11. pmc Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice
    Qizhi Tang
    Diabetes Center, Department of Medicine, University of California, San Francisco 94143, USA
    Nat Immunol 7:83-92. 2006
    ..Such persistent T(reg) cell-dendritic cell contacts preceded the inhibition of T(H) cell activation by dendritic cells, supporting the idea that dendritic cells are central to T(reg) cell function in vivo...
  12. doi request reprint T regulatory cells in autoimmune diabetes: past challenges, future prospects
    Jeffrey A Bluestone
    UCSF Diabetes Center, San Francisco, CA 94143, USA
    J Clin Immunol 28:677-84. 2008
    ..The development of type 1 diabetes in the NOD mouse strain it is a complex process that depends on a fine balance between pathogenic and regulatory pathways...
  13. ncbi request reprint Regulatory T-cell physiology and application to treat autoimmunity
    Qizhi Tang
    UCSF Diabetes Center, Department of Medicine and Department of Pathology, University of California, San Francisco, CA 94143 0540, USA
    Immunol Rev 212:217-37. 2006
    ....
  14. pmc Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway
    Brian T Fife
    UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, and Transplantation Research Center, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Exp Med 203:2737-47. 2006
    ....
  15. pmc Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice
    Mark A Travis
    Lung Biology Center, Department of Medicine, University of California San Francisco, 1550 4th Street, Room 545, San Francisco, California 94158, USA
    Nature 449:361-5. 2007
    ....
  16. pmc B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice
    Patrizia Scapini
    Department of Laboratory Medicine and Microbiology Immunology, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 108:E823-32. 2011
    ....
  17. ncbi request reprint Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice
    Emma L Masteller
    Diabetes Center, Department of Medicine, University of California, San Francisco, CA 94143 0540, USA
    J Immunol 175:3053-9. 2005
    ..These results provide a direct demonstration of the presence of autoantigen-specific T(reg) in the natural setting that can be applied as therapeutics for organ-specific autoimmunity...
  18. pmc Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells
    Cristina Penaranda
    Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA
    J Immunol 187:2015-22. 2011
    ..Taken together, the results suggest that FNB anti-CD3 therapy promotes tolerance by restoring the balance between pathogenic and regulatory T cells...
  19. ncbi request reprint Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function
    Qizhi Tang
    UCSF Diabetes Center, University of California San Francisco, San Francisco, CA 94143 0540, USA
    Eur J Immunol 34:2996-3005. 2004
    ..These results help explain contradictions in the literature and support the existence of functionally distinct Treg...
  20. ncbi request reprint Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells
    Kenneth J Scalapino
    Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco Veterans Affairs Medical Center, CA 94121, USA
    J Immunol 177:1451-9. 2006
    ....
  21. ncbi request reprint Imaging the function of regulatory T cells in vivo
    Qizhi Tang
    University of California, San Francisco UCSF Diabetes Center, Department of Medicine, 94143 0511, USA
    Curr Opin Immunol 18:496-502. 2006
    ..Expansion of such analysis to peripheral tissues together with the development of functional reporter mice will help to further elucidate the mode of operation of Tregs in vivo...
  22. ncbi request reprint How do CD4+CD25+ regulatory T cells control autoimmunity?
    Jeffrey A Bluestone
    University of California at San Francisco Diabetes Center, Department of Medicine, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, California 94143 0540, USA
    Curr Opin Immunol 17:638-42. 2005
    ..Recent in vivo analyses support a model in which Tregs directly or indirectly alter the activation and differentiation of pathogenic T cells through an effect on antigen presenting cells...
  23. pmc The Foxp3+ regulatory T cell: a jack of all trades, master of regulation
    Qizhi Tang
    Department of Surgery, University of California, San Francisco, San Francisco, California 94143, USA
    Nat Immunol 9:239-44. 2008
    ..Thus, the versatility and adaptability of the Foxp3+ T(reg) cells may in fact be the best argument that these cells are 'multitalented masters of immune regulation'...
  24. pmc Maternal T cells limit engraftment after in utero hematopoietic cell transplantation in mice
    Amar Nijagal
    Eli and Edythe Broad Center of Regeneration Medicine, San Francisco, California, USA
    J Clin Invest 121:582-92. 2011
    ..Our study suggests that the clinical success of IUHCTx may be improved by transplanting cells matched to the mother...
  25. pmc Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells
    Jeffrey A Bluestone
    Diabetes Center, Department of Medicine, University of California, San Francisco, CA 94143 0540, USA
    Proc Natl Acad Sci U S A 101:14622-6. 2004
    ..Emphasis will be placed on approaches to exploit regulatory T cells either directly or through the use of anti-CD3 immunotherapy...

Research Grants1

  1. "Regulatory 'T' Cell Control of Autoimmune Diabetes".
    Qizhi Tang; Fiscal Year: 2010
    ..The insight gained from these mechanistic studies will help to improve the design of regulatory T cell-based therapy for patients and to identify new targets for therapeutic intervention of type 1 diabetes. ..